Good news! Cancer is history (soon)! This might even be effective against recurrent cancer!
"... the researchers demonstrated that by attaching disc-shaped microparticles called “backpacks” to neutrophils, they could switch the cells into their anti-tumor (N1) state and keep them in that state. When these treated neutrophils were infused into mice with cancer, they activated other immune cells against the disease, including natural killer (NK) cells and T cells. Treated mice had smaller tumors and lived longer than untreated mice, and the results were even better when the backpack-bearing neutrophils were combined with common “checkpoint inhibitor” cancer drugs. ...
When the researchers combined their neutrophil treatment with a standard checkpoint inhibitor drug for cancer (anti-CTLA-4), mice with melanoma displayed significantly slowed tumor growth and improved survival rates. 67% of the animals survived beyond 40 days, and 33% achieved complete remission within 60 days. When these mice were rechallenged with another injection of melanoma cells, none of them developed cancer a second time, indicating that their immune systems had generated a robust anti-tumor memory response. ..."
From the abstract:
"Tumour-associated neutrophils can exert antitumour effects but can also assume a pro-tumoural phenotype in the immunosuppressive tumour microenvironment. Here we show that neutrophils can be polarized towards the antitumour phenotype by discoidal polymer micrometric ‘patches’ that adhere to the neutrophils’ surfaces without being internalized. Intravenously administered micropatch-loaded neutrophils accumulated in the spleen and in tumour-draining lymph nodes, and activated splenic natural killer cells and T cells, increasing the accumulation of dendritic cells and natural killer cells. In mice bearing subcutaneous B16F10 tumours or orthotopic 4T1 tumours, intravenous injection of the micropatch-loaded neutrophils led to robust systemic immune responses, a reduction in tumour burden and improvements in survival rates. Micropatch-activated neutrophils combined with the checkpoint inhibitor anti-cytotoxic T-lymphocyte-associated protein 4 resulted in strong inhibition of the growth of B16F10 tumours, and in complete tumour regression in one-third of the treated mice. Micropatch-loaded neutrophils could provide a potent, scalable and drug-free approach for neutrophil-based cancer immunotherapy."
Neutrophils bearing adhesive polymer micropatches as a drug-free cancer immunotherapy (no public access)
A neutrophil (purple) carries an empty “backpack” (pink) made of polymers.
No comments:
Post a Comment